<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02437409</url>
  </required_header>
  <id_info>
    <org_study_id>T01-072012</org_study_id>
    <nct_id>NCT02437409</nct_id>
  </id_info>
  <brief_title>Acute Recanalization of Thrombo-Embolic Ischemic Stroke With pREset (ARTESp)</brief_title>
  <acronym>ARTESp</acronym>
  <official_title>Acute Recanalization of Thrombo-Embolic Ischemic Stroke With pREset (ARTESp)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phenox GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Phenox GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ARTESp is a prospective multicenter study in which the pREset thrombectomy system (phenox
      GmbH* Germany) will be examined. The effectiveness, safety and the long-term success when
      using the pREset to treat acute occlusions of cerebral vessels will be analyzed.

      *German: &quot;Gesellschaft mit beschränkter Haftung&quot;, limited liability company
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ARTESp is a prospective multicenter study in which the pREset thrombectomy system (phenox
      GmbH Germany) will be examined. The effectiveness, safety and the long-term success when
      using the pREset to treat acute occlusions of cerebral vessels will be analyzed.

      In this study the market-approved, self-expandable stent retriever (pREset, phenox GmbH,
      Germany) will be used to achieve a direct flow recovery.

      The thrombectomy system will be unfolded directly in the vessel occlusion. In a second step,
      the system and the thrombus will be pulled back into the guide catheter.

      It is planned to enroll 100 patients at the age of 18 until 85 years, with a NIHSS (National
      Institutes of Health Stroke Scale) ≥ 8 and ≤ 30. The preconditions for study enrollment are
      the written consent of the patient or of the legal representative and the fulfillment of all
      mentioned inclusion and exclusion criteria. Pregnant women are excluded from study
      participation.The clinical interventions are in accordance with the clinical standard of care
      for the treatment of this patient population.

      The mRS (Modified Rankin Scale) on day 30, the NIHSS on day 90 and an imaging procedure on
      day 90 may be performed by the study site provided that it corresponds to the clinical
      standards of the study site.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological Condition of the Patient</measure>
    <time_frame>90 days after treatment</time_frame>
    <description>modified Rankin Scale (mRS)
Neurological Condition is measured by the &quot;Modified Rankin Scale (mRS)&quot;. This scale ranges from 0 - 6:
0 = No symptoms at all;
= able to carry out all usual duties and activities;
= unable to carry out all previous activities, but able to look after own affairs without assistance;
= requiring some help, but able to walk without assistance;
= unable to walk without assistance and unable to attend to own bodily needs without assistance;
= bedridden, incontinent and requiring constant nursing care and attention;
= dead</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological Condition of the Patient</measure>
    <time_frame>24 to 72 hr after treatment</time_frame>
    <description>The National Institutes of Health Stroke Scale (NIHSS) is a commonly used measure to assess the severity of a stroke. All items are rated and scores are added at the end. A higher score corresponds to a more severe stroke. Assessed are:
Level of Conciousness (LOC) (0-3) 1a. LOC Questions (0-2) 1b. LOC Commands (0-2)
Best Gaze (0-2)
Visual (0-3)
Facial palsy (0-3)
Motor arm (0-4)
Motor leg (0-4)
Limb ataxia (0-2)
Sensory (0-2)
Best Language (0-3)
Dysarthria (0-2)
Extinction and Inattention (0-2)
CLASSIFICATION:
0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke
As published by ninds.nih.gov: http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial Hemorrhage (ICH)</measure>
    <time_frame>24 hr after treatment</time_frame>
    <description>Intracranial hemorrhage was assessed via imaging material (e.g. Digital Subtraction Angiography - DSA or CT) as forwarded by the clinical sites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Groin Puncture to Recanalization</measure>
    <time_frame>during intervention, up to 3 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recanalization of the Target Vessel</measure>
    <time_frame>at the end of intervention, up to 3 hr</time_frame>
    <description>original Thrombolysis in Cerebral Infarction score (o-TICI) The TICI scale indicates perfusion of an occluded blood vessel, it is used in angiographic imaging.
Grade 0 = no perfusion Grade 1 = Penetration with minimal perfusion. The contrast material passes beyond the area of obstruction but fails to opacify the entire cerebral bed distal to the obstruction for the duration of the angiographic run, Grade 2a = Only partial filling (&lt;2/3) of the entire vascular territory is visualized, Grade 2b = Complete filling of all of the expected vascular territory is visualized, but the filling is slower than normal, Grade 3 = complete perfusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No. of Passages Needed to Reach the Final TICI Score With pREset</measure>
    <time_frame>during intervention, up to 3 hr</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">115</enrollment>
  <condition>Stroke</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pREset thrombectomy retriever</intervention_name>
    <description>Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        100 patients harboring an acute ischemic stroke in at least one of the major intracranial
        arteries
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age ≥ 18 and ≤ 85 years.

          -  Patients with acute-onset stroke in the 0-6 hour time window for cerebral onset of
             symptoms and in angiography with a TICI reperfusion (Thrombolysis in Cerebral
             Infarction) value of 0 or 1 of at least one major cerebral artery (carotid artery, A.
             media , anterior cerebral artery, basilar artery, vertebral artery, posterior cerebral
             artery).

          -  NIHSS (National Institutes of Health Stroke Scale) ≥ 8

          -  Signed Informed Consent by patient / legal representative to participate in the study.

        Exclusion Criteria:

          -  Pregnancy

          -  Demarcated infarcted area in the initial Cranial CT or intracranial haemorrhage,

          -  Rapid improvement of neurological symptoms

          -  NIHSS &gt; 30

          -  Anticoagulation with warfarin with INR (international normalized ratio) &gt; 3.0,

          -  Platelets &lt;30,000,

          -  Glucose &lt;50mg/dl,

          -  Life expectancy &lt;90 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Reith, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum des Saarlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Katharinenhospital</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.phenox.info</url>
    <description>phenox GmbH</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2015</study_first_submitted>
  <study_first_submitted_qc>May 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2015</study_first_posted>
  <results_first_submitted>September 3, 2015</results_first_submitted>
  <results_first_submitted_qc>October 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2015</results_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic, Acute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>115 patients started the study, but little by little, 15 patients were excluded/discontinued due to screening failure or withdrawn consent.</recruitment_details>
      <pre_assignment_details>No assignment to groups was performed due to single-arm study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Patients</title>
          <description>Treated with pREset Thrombectomy Retriever</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115">Eventually 100 evaluable patients, attrition rate of 15%</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100">In total 100 patients fulfilled the in-and exclusion criteria,15 patients were excluded/discontinued</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screening failure</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>Treated with pREset Thrombectomy Retriever</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.3" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Gender</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Neurological Condition of the Patient</title>
        <description>modified Rankin Scale (mRS)
Neurological Condition is measured by the &quot;Modified Rankin Scale (mRS)&quot;. This scale ranges from 0 - 6:
0 = No symptoms at all;
= able to carry out all usual duties and activities;
= unable to carry out all previous activities, but able to look after own affairs without assistance;
= requiring some help, but able to walk without assistance;
= unable to walk without assistance and unable to attend to own bodily needs without assistance;
= bedridden, incontinent and requiring constant nursing care and attention;
= dead</description>
        <time_frame>90 days after treatment</time_frame>
        <population>All Patients</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>Treated with pREset Thrombectomy Retriever</description>
          </group>
        </group_list>
        <measure>
          <title>Neurological Condition of the Patient</title>
          <description>modified Rankin Scale (mRS)
Neurological Condition is measured by the &quot;Modified Rankin Scale (mRS)&quot;. This scale ranges from 0 - 6:
0 = No symptoms at all;
= able to carry out all usual duties and activities;
= unable to carry out all previous activities, but able to look after own affairs without assistance;
= requiring some help, but able to walk without assistance;
= unable to walk without assistance and unable to attend to own bodily needs without assistance;
= bedridden, incontinent and requiring constant nursing care and attention;
= dead</description>
          <population>All Patients</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mRS 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mRS 0-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mRS 0-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mRS 3-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mRS 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost to follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurological Condition of the Patient</title>
        <description>The National Institutes of Health Stroke Scale (NIHSS) is a commonly used measure to assess the severity of a stroke. All items are rated and scores are added at the end. A higher score corresponds to a more severe stroke. Assessed are:
Level of Conciousness (LOC) (0-3) 1a. LOC Questions (0-2) 1b. LOC Commands (0-2)
Best Gaze (0-2)
Visual (0-3)
Facial palsy (0-3)
Motor arm (0-4)
Motor leg (0-4)
Limb ataxia (0-2)
Sensory (0-2)
Best Language (0-3)
Dysarthria (0-2)
Extinction and Inattention (0-2)
CLASSIFICATION:
0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke
As published by ninds.nih.gov: http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf</description>
        <time_frame>24 to 72 hr after treatment</time_frame>
        <population>All Patients</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>Treated with pREset Thrombectomy Retriever</description>
          </group>
        </group_list>
        <measure>
          <title>Neurological Condition of the Patient</title>
          <description>The National Institutes of Health Stroke Scale (NIHSS) is a commonly used measure to assess the severity of a stroke. All items are rated and scores are added at the end. A higher score corresponds to a more severe stroke. Assessed are:
Level of Conciousness (LOC) (0-3) 1a. LOC Questions (0-2) 1b. LOC Commands (0-2)
Best Gaze (0-2)
Visual (0-3)
Facial palsy (0-3)
Motor arm (0-4)
Motor leg (0-4)
Limb ataxia (0-2)
Sensory (0-2)
Best Language (0-3)
Dysarthria (0-2)
Extinction and Inattention (0-2)
CLASSIFICATION:
0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke
As published by ninds.nih.gov: http://www.ninds.nih.gov/doctors/NIH_Stroke_Scale.pdf</description>
          <population>All Patients</population>
          <units>NIHSS score</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intracranial Hemorrhage (ICH)</title>
        <description>Intracranial hemorrhage was assessed via imaging material (e.g. Digital Subtraction Angiography - DSA or CT) as forwarded by the clinical sites.</description>
        <time_frame>24 hr after treatment</time_frame>
        <population>All Patients</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>Treated with pREset Thrombectomy Retriever</description>
          </group>
        </group_list>
        <measure>
          <title>Intracranial Hemorrhage (ICH)</title>
          <description>Intracranial hemorrhage was assessed via imaging material (e.g. Digital Subtraction Angiography - DSA or CT) as forwarded by the clinical sites.</description>
          <population>All Patients</population>
          <units>patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Groin Puncture to Recanalization</title>
        <time_frame>during intervention, up to 3 hr</time_frame>
        <population>All Patients</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>Treated with pREset Thrombectomy Retriever</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Groin Puncture to Recanalization</title>
          <population>All Patients</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="6" upper_limit="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recanalization of the Target Vessel</title>
        <description>original Thrombolysis in Cerebral Infarction score (o-TICI) The TICI scale indicates perfusion of an occluded blood vessel, it is used in angiographic imaging.
Grade 0 = no perfusion Grade 1 = Penetration with minimal perfusion. The contrast material passes beyond the area of obstruction but fails to opacify the entire cerebral bed distal to the obstruction for the duration of the angiographic run, Grade 2a = Only partial filling (&lt;2/3) of the entire vascular territory is visualized, Grade 2b = Complete filling of all of the expected vascular territory is visualized, but the filling is slower than normal, Grade 3 = complete perfusion.</description>
        <time_frame>at the end of intervention, up to 3 hr</time_frame>
        <population>100 patients harboured 109 vessel occlusions</population>
        <group_list>
          <group group_id="O1">
            <title>Occluded Vessels</title>
            <description>100 patients harboured 109 vessel occlusions</description>
          </group>
        </group_list>
        <measure>
          <title>Recanalization of the Target Vessel</title>
          <description>original Thrombolysis in Cerebral Infarction score (o-TICI) The TICI scale indicates perfusion of an occluded blood vessel, it is used in angiographic imaging.
Grade 0 = no perfusion Grade 1 = Penetration with minimal perfusion. The contrast material passes beyond the area of obstruction but fails to opacify the entire cerebral bed distal to the obstruction for the duration of the angiographic run, Grade 2a = Only partial filling (&lt;2/3) of the entire vascular territory is visualized, Grade 2b = Complete filling of all of the expected vascular territory is visualized, but the filling is slower than normal, Grade 3 = complete perfusion.</description>
          <population>100 patients harboured 109 vessel occlusions</population>
          <units>number of vessels</units>
          <param>Number</param>
          <units_analyzed>vessel occlusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>vessel occlusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TICI 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TICI 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TICI 2a</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TICI 2b</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TICI 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>No. of Passages Needed to Reach the Final TICI Score With pREset</title>
        <time_frame>during intervention, up to 3 hr</time_frame>
        <population>100 patients harboured 109 vessel occlusions</population>
        <group_list>
          <group group_id="O1">
            <title>Occluded Vessels</title>
            <description>100 patients harboured 109 vessel occlusions</description>
          </group>
        </group_list>
        <measure>
          <title>No. of Passages Needed to Reach the Final TICI Score With pREset</title>
          <population>100 patients harboured 109 vessel occlusions</population>
          <units>passes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>vessel occlusions</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>vessel occlusions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days after procedure</time_frame>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>Treated with pREset Thrombectomy Retriever</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Mortality</sub_title>
                <description>Led to death</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vasospasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Emboli to a new territory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Emboli to the same territory</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Focal subarachnoid hemorrhages around the target vessel</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PH I</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>PH II</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Data must only be published after completion of the study. Publication of e.g. single center experience within the study is not allowed until the aggregate data have been submitted.
All information and data generated in association with this study will be held in strict confidence and remain in the sole property of phenox GmbH. The investigator agrees to use this information for the sole purpose of completing this study and for no other purpose without written consent from phenox GmbH.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Affairs</name_or_title>
      <organization>phenox GmbH</organization>
      <phone>+49 (0)234 36 919 ext 0</phone>
      <email>ARTESp@phenox.info</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

